Introduction {#sec1_1}
============

Genital warts (GW; condylomata acuminata) are a very common and contagious sexually transmitted disease caused by skin infection with human papillomavirus (HPV) \[[@B1]\]. HPV has a specific tropism for squamous stratified epithelium \[[@B2]\]. This infection is in general acquired through direct genital contact. Minor trauma facilitates the penetration of the virus. Penile shaft, glans, vulvar and perianal regions are commonly affected \[[@B3]\]. HPV infection is characterized by a relevant immune evasion mechanism that inhibits and delays the host immune response to the virus \[[@B4]\]. Genotypes 6 and 11 are the most common HPV involved in GW formation \[[@B5]\]. GW lesions manifest as variable in size and shape. Lesions could be soft papules or plaques on anogenital skin. Cryotherapy, podophyllotoxin, imiquimod, and laser therapy are commonly used in GW \[[@B6]\]. However, available treatments are in general still unsatisfactory due to low efficacy and clearance rate, low local tolerability, and high recurrence rate \[[@B7]\]. Topical Polyphenon E 10% has been recently evaluated in immunocompetent subjects with multiple GW \[[@B8]\]. Polyphenon E, applied 3 times a day for up to 16 weeks, induced a complete clearance rate in more than 50% of patients \[[@B9]\]. In addition, the recurrence rate at 3 months after the conclusion of the therapy was particularly low (\<6%) \[[@B9]\]. Polyphenon E is a quantified extract of green tea leaves (*Camellia sinensis*) where the main active substance is epigallocatechin gallate (EGCG), a polyphenol substance which represents the major component of the catechin fraction \[[@B10]\]. EGCG has potent antioxidant, anti-inflammatory and proapoptotic actions, which could explain its antiviral properties \[[@B11]\]. Recent data have shown that EGCG is able to modulate the cellular genes involved in Toll-like receptor production and in the mechanisms of apoptosis \[[@B12]\]. The product has shown a general good safety profile. Local skin reactions like erythema and edema, in general mild to moderate, were reported in most treated subjects \[[@B13]\]. No data are available regarding the efficacy and the tolerability of Polyphenon E in immunocompromised subjects. We report the clinical efficacy and the tolerability of Polyphenon E 10% ointment (Veregen^TM^; Medigene, Germany) in an HIV-positive subject with multiple "difficult-to-treat" GW.

Case Description {#sec1_2}
================

A 55-year-old man, nonsmoker, with a HIV-positive history came to our attention in February 2017. He was on treatment with Stribild^TM^, 1 capsule daily (150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 245 mg tenofovir disoproxil). The CD4+/CD8+ cellular count was 326/µL (normal values: 404--1,612); the CD3+/CD8+ cellular count was 819/µL (normal values: 220--1,219). The CD4/CD8 ratio was 0.40 (normal value: \>1). Several typical GW lesions were present at the penis shaft and at the level of the neck and the corona of glans (Fig. [1](#F1){ref-type="fig"}). These lesions were present for 2 years. Several cryotherapy sessions (a total of 10 procedures) had been performed with partial success. At the initial visit a total number of 5 lesions were present (Fig. [1](#F1){ref-type="fig"}). Treatment with topical Polyphenon E 10% 3 times a day was prescribed and started. After 1 month of treatment the lesions were reduced to 2. Treatment was very well tolerated. After 8 weeks of treatment no more lesions were observed and therefore a complete clearance was obtained (Fig. [2](#F2){ref-type="fig"}). Local tolerability was evaluated to be very good by the patient.

Discussion {#sec1_3}
==========

Polyphenon E ointment is considered an effective, well-tolerated, self-applicable topical treatment of GW in immunocompetent subjects \[[@B14]\]. Clinical efficacy and tolerability was evaluated in randomized vehicle-controlled phase III trials in more than 1,000 patients \[[@B15]\]. A complete clearance rate was observed in 51% of the treated subjects. The mean treatment duration for complete clearance was between 14 and 16 weeks \[[@B16]\]. GW are very common in immunocompromised subjects \[[@B17]\]. HIV infection appears to alter the natural history of HPV-associated lesions and oncogenesis \[[@B18]\], and HIV-positive patients have a substantial high risk of suffering from GW in comparison with HIV-negative immunocompetent subjects. HIV-positive patients often develop multiple papillomatous lesions in the genital area and also in the extragenital area such as the oral cavity \[[@B19]\]. Goldstone et al. \[[@B20]\] have demonstrated that in HIV subjects the prevalence of any tested HPV type was 18.5% in the penis, 17.1% in the scrotum, 33.0% in the perineal/perianal region, 42.4% in the anal canal, and 48.0% at any site. Antiretroviral therapy is not able to prevent the development of HPV-associated lesions and does not eliminate HPV infection \[[@B21]\]. The treatment of GW in immunocompromised subjects can be particularly disappointing. Data regarding the efficacy of Polyphenon E in immunocompromised subjects are so far lacking. EGCG has an antiviral action through pathways triggering cell growth arrest and increasing proapoptotic molecules like p53 and p16 \[[@B22]\]. EGCG is able to interfere with the cellular activity of E6 and E7, 2 HPV virus proteins \[[@B23]\]. E6 and E7 are involved in the process of apoptosis inhibition and in the mechanisms of immune evasion \[[@B24]\]. Therefore, Polyphenon E could express anti-HPV action through multiple mechanisms. The gene modulation expressed by EGCG could be of help in fighting HPV lesions in HIV patients. In this case report, we have shown a high clinical efficacy of Polyphenon E in the treatment of multiple "difficult-to-treat" GW in an HIV-positive subject. It is remarkably that complete clearance of GW lesions was achieved in only 8 weeks of treatment, which is a shorter treatment period in comparison with the mean duration of treatment for GW clearance in immunocompetent patients. This case report suggests that topical Polyphenon E 10% could be an effective therapeutic strategy in subjects with GW and immunosuppression. Specific controlled trials in this specific population are warranted.
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